Obsessive-compulsive Disorder
Conditions
Keywords
propanolol, obsessive-compulsive disorder
Brief summary
The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.
Detailed description
Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear reactivation procedure. Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention
Interventions
DRUGPropanolol
Active treatment
DRUGPlacebo
Sponsors
New York State Psychiatric Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Principal Diagnosis of Obsessive-Compulsive Disorder
Exclusion criteria
* History of other serious psychiatric disorder * Current Major Depressive Disorder * Women who are pregnant or nursing * Current use of psychiatric medication * Persons planning to start another treatment during the study period * Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Yale Brown Obsessive-Compulsive Scale | 2 weeks | Total score on this Clinician-administered measure of OCD symptoms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Behavioral Avoidance Task | 2 weeks | Total number of steps completed (0-5) on this task assessing avoidance of OCD triggers |
Countries
United States
Outcome results
None listed